rs10889677 — IL23R

IL23R rs10889677 — The miRNA Gate: Regulating a Cytokine Receptor Across Multiple Autoimmune Fronts

IL23R¹¹ IL23R
Interleukin-23 receptor gene on chromosome 1p31.3; encodes the ligand-binding subunit of the IL-23 receptor complex that pairs with IL12RB1 to signal through JAK2/STAT3 encodes the receptor subunit that binds interleukin-23 — the cytokine that drives Th17 cell differentiation²² Th17 cell differentiation
Th17 cells are a pro-inflammatory CD4+ T cell subset that produce IL-17A, IL-17F, and IL-22; they are central to mucosal immunity but also drive tissue damage in multiple autoimmune diseases, a cell population central to chronic autoimmune inflammation in the gut, joints, eyes, and skin. The rs10889677 variant sits at the 3' end of the IL23R gene, in a region where the transcript's 3' untranslated region (3' UTR) and downstream intronic sequences overlap across different mRNA isoforms — placing this SNP at a molecular bottleneck that governs how much IL-23 receptor protein your cells ultimately produce.

The Mechanism

The rs10889677 A allele disrupts a recognition sequence within the IL23R 3' UTR targeted by Let-7e and Let-7f³³ Let-7e and Let-7f
members of the let-7 microRNA family, broadly expressed post-transcriptional regulators that suppress gene expression by binding the 3' UTR and reducing mRNA stability or translation — two microRNAs in the let-7 family that normally bind this region and suppress IL23R mRNA translation. When the A allele disrupts this binding site, Let-7e and Let-7f lose their grip on the transcript, allowing more IL-23 receptor protein to accumulate on immune cell surfaces. The result is a cell that is more sensitive to IL-23 signaling — and therefore more prone to Th17 activation and the downstream inflammatory cascade (IL-17A, IL-17F, IL-22) that those cells produce.

The variant is located at GRCh38 chr1:67,259,437, in a region classified as a 3' UTR variant in the canonical IL23R transcript (NM_144701.3: c.*309C>A) and as deep intronic in longer isoforms (c.1239+3510C>A). Both classifications converge on the same functional conclusion: this is a post-transcriptional regulatory variant, not a protein-coding change, operating through altered miRNA-mediated silencing.

The Evidence

The most striking association emerged in a study of Graves' ophthalmopathy (thyroid eye disease) — a condition where the orbital tissues behind the eye are infiltrated by activated T cells and fibroblasts, causing proptosis, diplopia, and, in severe cases, vision loss. Huber et al. (2008)⁴⁴ Huber et al. (2008)
Huber AK, Jacobson EM, Jazdzewski K, Concepcion ES, Tomer Y. IL23R is a major susceptibility gene for Graves' ophthalmopathy. J Clin Endocrinol Metab. 2008;93:1077-81 studied 216 North American Caucasians with Graves' disease and 368 healthy controls, finding that the C allele at rs10889677 appeared in 78.6% of patients with ophthalmopathy versus 64.5% of controls (OR=2.03, P=1.3×10⁻⁴), and that the CC genotype was present in 62.1% of ophthalmopathy patients versus 41.0% of controls (OR=2.36, P=1.4×10⁻⁴). This was a striking signal for a variant affecting an organ-specific complication rather than the underlying thyroid autoimmunity itself — only three of the four SNPs tested were associated with GO rather than Graves' disease broadly, suggesting that IL-23/Th17 signaling has a particular role in driving the orbital inflammatory component.

However, the directionality at rs10889677 deserves careful attention. In the larger body of IBD and spondyloarthritis research, the A allele is the risk allele⁵⁵ A allele is the risk allele
consistent with the GWAS Catalog annotation of rs10889677-A for ulcerative colitis at OR=1.29, P=1×10⁻⁸. A meta-analysis of 16 studies comprising 6,450 ankylosing spondylitis cases and 8,009 controls⁶⁶ 6,450 ankylosing spondylitis cases and 8,009 controls
Han et al. Clin Chim Acta 2018 found the A allele increased AS risk with OR=1.136 (95% CI 1.043–1.236, P=0.003) overall, rising to OR=1.192 (95% CI 1.080–1.315, P<0.001) in Europeans. A 31-study meta-analysis confirmed⁷⁷ confirmed
Zhang et al. Autoimmunity 2022 the A allele as a significant risk factor for both AS and rheumatoid arthritis in the general population, with the strongest effects in Caucasians and the AA genotype driving risk in Mongolian populations.

The functional interpretation aligns with the miRNA data: the A allele impairs Let-7 suppression, increasing IL-23 receptor density on Th17 precursors and amplifying the IL-23→Th17→IL-17A inflammatory loop that drives gut mucosa and joint inflammation. The Graves' ophthalmopathy finding with the C allele may reflect a distinct mechanism in orbital fibroblasts — where higher IL-23R expression could paradoxically promote anti-inflammatory resolution signaling — or may represent a population-specific LD pattern not replicated in other cohorts. Notably, a Japanese AITD study⁸⁸ Japanese AITD study
Ban et al. Autoimmunity 2009 found no association of rs10889677 with Graves' disease or ophthalmopathy in 290 GD patients, suggesting the GO association may be Caucasian-specific or require replication in larger cohorts.

Practical Implications

The primary clinical relevance of rs10889677 is as a contributor to the IL-23/Th17 inflammatory axis that underpins multiple autoimmune and inflammatory conditions. For A allele carriers, this variant sits within a broader IL23R haplotype block that has been consistently associated with susceptibility to Crohn's disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, and psoriasis. The A allele does not cause disease — it lowers the threshold for IL-23-driven inflammatory escalation, particularly in contexts of gut barrier disruption, axial joint stress, or other triggers of innate immune activation.

Blocking the IL-23 pathway has become a validated therapeutic strategy: IL-23-targeting biologics (risankizumab⁹⁹ risankizumab
an anti-IL-23p19 monoclonal antibody approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and PsA, guselkumab, tildrakizumab) show efficacy across exactly the conditions associated with IL23R risk variants. A allele carriers who develop refractory inflammatory bowel disease or spondyloarthritis are biologically well-matched to this drug class.

Interactions

rs10889677 resides in LD block 2 of the IL23R locus, which also contains the well-characterized missense variant rs11209026 (R381Q) — the only functionally characterized IL23R variant that directly reduces receptor signaling. The two variants are co-inherited on a protective haplotype in which both the rs11209026 Q allele and the rs10889677 C allele travel together. The rs10489629 variant, in the same haplotype block, tags a similar protective signal for Crohn's disease and AS. These variants should be interpreted together — a carrier of multiple risk alleles across this block accumulates additive IL-23R upregulation effects.